ABBN.SW: $86.10 ▼ -2.46 (-2.78%)ASML.AS: $1,560.80 ▼ -95.00 (-5.74%)ENR.DE: $162.50 ▲ 0.00 (0.00%)GLEN.L: $537.30 ▲ 2.00 (0.37%)IFX.DE: $80.56 ▲ 0.00 (0.00%)NOKIA.HE: $12.11 ▲ 0.11 (0.92%)RIO.L: $7,280.00 ▲ 16.00 (0.22%)AMD: $519.85 ▼ -31.78 (-5.76%)INTC: $132.28 ▼ -8.66 (-6.14%)MU: $1,051.77 ▼ -159.61 (-13.18%)WDC: $670.75 ▼ -61.87 (-8.45%)AAPL: $294.30 ▼ -2.71 (-0.91%)AMZN: $234.11 ▲ 1.32 (0.57%)NVDA: $200.04 ▼ -8.61 (-4.13%)AMAT: $585.88 ▼ -54.30 (-8.48%)CIEN: $459.85 ▼ -0.48 (-0.10%)STX: $1,038.59 ▼ -55.45 (-5.07%)

Company Details

Enveric Biosciences, Inc.

ENVB - NASDAQ

Identifiants & Marche

Ticker ENVB
ISIN US29405E2081
CIK 0000890821
Bourse NASDAQ
Devise USD

Classification

Secteur Healthcare
Industrie Biotechnology

Entreprise

Pays US
Siege N/A
Fondee N/A
Site Web Lien

Description

Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy. Enveric Biosciences, Inc. is headquartered in Naples, Florida.
Voir l'evolution du cours Retour